Cargando…
Adjuvant Hormonotherapy and Cardiovascular Risk in Post-Menopausal Women with Breast Cancer: A Large Population-Based Cohort Study
SIMPLE SUMMARY: For post-menopausal women with estrogen-receptor-positive breast cancer, treatment with aromatase inhibitors reduces disease recurrence and mortality, as compared to tamoxifen. Nevertheless, women treated with aromatase inhibitors more often develop hyperlipidemia, hypercholesterolem...
Autores principales: | Franchi, Matteo, Tritto, Roberta, Tarantini, Luigi, Navazio, Alessandro, Corrao, Giovanni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8125834/ https://www.ncbi.nlm.nih.gov/pubmed/34066685 http://dx.doi.org/10.3390/cancers13092254 |
Ejemplares similares
-
Cardiovascular Risk After Adjuvant Trastuzumab in Early Breast Cancer: An Italian Population‐Based Cohort Study
por: Franchi, Matteo, et al.
Publicado: (2020) -
Radioablation +/− hormonotherapy for prostate cancer oligorecurrences (Radiosa trial): potential of imaging and biology (AIRC IG-22159)
por: Marvaso, Giulia, et al.
Publicado: (2019) -
Effectiveness and Healthcare Cost of Adding Trastuzumab to Standard Chemotherapy for First-Line Treatment of Metastatic Gastric Cancer: A Population-Based Cohort Study
por: Franchi, Matteo, et al.
Publicado: (2020) -
Brain Neural Progenitors are New Predictive Biomarkers for Breast Cancer Hormonotherapy
por: Basseville, Agnes, et al.
Publicado: (2022) -
Impact of adjuvant hormonotherapy on radiation-induced breast fibrosis according to the individual radiosensitivity: results of a multicenter prospective French trial
por: Bourgier, Céline, et al.
Publicado: (2018)